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Abstract
Objectives: Selected patients with unresectable colorectal liver metastases (CLM) may be rendered
resectable using the two-stage hepatectomy (TSH) approach. This review was conducted with the aim of
collating and evaluating published evidence for TSH in patients with initially unresectable CLM.
Methods: Searches of the MEDLINE and EMBASE databases were undertaken to identify studies of
TSH in patients with initially unresectable CLM. Studies were required to focus on the perioperative
treatment regimen, operative strategy, morbidity, technical success and survival outcomes.
Results: Ten observational studies were reviewed. A total of 459 patients with initially unresectable CLM
were selected for the first stage of TSH. Preoperative chemotherapy was used in 88% of patients and
achieved partial and stable response rates of 59% and 39%, respectively. Postoperative morbidity and
mortality after the first stage of TSH were 17% and 0.5%, respectively. Portal vein embolization (PVE) was
used in 76% of patients. Ultimately, 352 of the initial 459 (77%) patients underwent the second stage of
TSH. Major liver resection was undertaken in 84% of patients; the negative margin (R0) resection rate was
75%. Postoperative morbidity and mortality after the second stage of TSH were 40% and 3%, respec-
tively. Median overall survival was 37 months (range: 24–44 months) in patients who completed both
stages of TSH. In patients who did not complete both stages of TSH, median survival was 16 months
(range: 10–29 months). The 3-year disease-free survival rate was 20% (range: 6–27%).
Conclusions: Two-stage hepatectomy is safe and effective in selected patients with initially unresect-
able CLM. Further studies are required to better define patient selection criteria for TSH and the exact
roles of PVE and preoperative and interval chemotherapy.
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Introduction
Colorectal cancer is the third most common cancer worldwide.1
Around 25% of patients have synchronous liver metastases at
presentation and a further 25–50% subsequently develop meta-
chronous liver disease.2,3 Surgical resection of colorectal liver
metastases (CLM) is considered the only curative therapy and
achieves 5-year overall survival (OS) rates of up to 58%.4–11 Nev-
ertheless, fewer than 25% of patients with CLM are considered
to have resectable disease.11–13 In the last decade, considerable
efforts were directed towards developing strategies to increase
the number of patients with CLM who could benefit from
surgical resection. In 2000, Adam et al. published the first series
of two-stage hepatectomies (TSHs) in patients with unresectable
bilobar CLM that were not amenable to resection in a single
operation, even in combination with preoperative chemotherapy
and portal vein embolization (PVE).14 Two-stage hepatectomy is
conceived as a planned and potentially curative strategy and
consists of the resection of CLM in one hemiliver during the
first stage, followed by a second resection of CLM in the con-
tralateral hemiliver during the second stage. This systematic
review was undertaken to assess the published evidence for the
safety and efficacy of TSH in patients with initially unresectable
CLM.
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Materials and methods
Literature search strategy
A search of the MEDLINE (1966 to June 2012) and EMBASE
(January 1974 to June 2012) databases was undertaken. The
search terms colorectal cancer or colorectal neoplasm, liver metas-
tases or hepatic metastases tumour, hepatectomy or liver resection or
hepatic resection, and stage resection or two-stage hepatectomy were
used. These terms were mapped to MESH (medical subject head-
ings) terms and were searched for as text items. Reference lists
from relevant articles were searched and the authors’ personal
libraries were checked manually for other potentially relevant
studies. No search was made of unpublished literature.
Study selection
The study evaluation was performed by two reviewers (VWTL
and JML). Reviews, case reports, conference abstracts, non-
human studies and case series in which TSH was completed in
fewer than 10 patients were excluded. Abstracts of the remaining
studies were retrieved and reviewed for relevance. The full texts of
previously selected articles were thoroughly reviewed. Studies on
which a decision could not be made based upon the abstract were
also reviewed. Those studies which described the use of TSH with
curative intent in patients with initially unresectable CLM were
included for analysis. Studies that adopted hybrid approaches,
combining liver resection with ablation techniques, or the resec-
tion of extrahepatic metastases with the aim of expanding the
criteria for resection of CLM, were also included for review. Only
studies reporting both short- and longterm outcomes of TSH
were included. When multiple publications were identified from
the same or overlapping patient series, only the most complete or
recent publication was included. Study methodology quality was
assessed according to the Newcastle–Ottawa scale.15 A score of 4
was required for inclusion.
Data extraction and critical appraisal
Two reviewers (VWTL and JML) independently appraised each
article using predefined criteria. Data extracted included informa-
tion on methodology, quality criteria, setting of the use of peri-
operative chemotherapy, response to chemotherapy, proportion
of negative margin (R0) resections, disease-free survival (DFS)
and OS, and morbidity and mortality in this multimodal
approach. Discrepancies were resolved by consensus. Major hepa-
tectomy was defined as the resection of three or more Couinaud
segments. Because the reports included lacked control groups and
the selected studies were heterogeneous, no meta-analysis could
be carried out. A qualitative systematic review was performed
without a comparator group by full tabulation of the results. The
level of evidence of each article was scored according to the Hier-
archy of Evidence table developed by the National Health and
Medical Research Council of Australia.16 This systematic review
was performed according to PRISMA (preferred reporting items
for systematic reviews and meta-analyses) guidelines.17
Results
The literature search using the strategy described herein identified
226 studies. Duplicated studies, non-human studies, review arti-
cles, case reports and conference abstracts were excluded. The
manuscripts of the 43 remaining articles were reviewed. Thirty-
three articles that did not fulfil the inclusion criteria were
excluded. The remaining 10 studies were individually reviewed
(Fig. 1). No meta-analyses or randomized controlled trials (RCTs)
were identified. Ten observational studies (Level IV evidence)
were included for analysis.
This review pertains to 10 studies covering a combined total
of 459 patients with unresectable CLM in whom the first stage of
TSH was performed.18–27 One study, reporting TSH for initially
unresectable liver metastases in 33 patients with colorectal
cancer, three with neuroendocrine tumours, one with a gastroin-
testinal stromal tumour, one with ocular melanoma and one
with salivary gland carcinoma, was included for analysis.22 Three
studies with overlapping patient series28–30 were excluded, as was
one study without longterm survival data.31 Three studies from
the same institution reporting the use of ablation of CLM only
at the first stage of TSH were excluded.32–34 Criteria used to
define patients as initially unresectable were reported in eight
studies (Table 1).18–22,24,25,27 Insufficient volume of the future liver
remnant (FLR) was the most frequently documented reason for
the designation of unresectability (six of eight studies).18–22,25
However, these studies did not uniformly identify an adequate
FLR volume. Six studies reported patient selection criteria for
TSH, but none of them used the same criteria (Table 1).18–20,23,26,27
Five studies included patients with extrahepatic disease in whom
total metastasectomy was feasible and planned.20–22,24,27 Ten
studies reported the number of patients with synchronous color-
ectal cancer and liver metastases; collectively, these patients rep-
resented 78% (range: 50–96%) of all patients (350 of 451
patients).18–27 Preoperative chemotherapy was administered to
some patients in all 10 studies: 400 of 457 patients (88%; range:
64–100%) received chemotherapy.18–27 Five studies reported the
rate of response to preoperative chemotherapy; partial response
was achieved in 130 of 222 patients (59%; range: 43–73%) and
stable response was achieved in 86 of 222 patients (39%; range:
19–57%).19,20,23,24,27
The surgical characteristics and perioperative outcomes of the
first stage of TSH are depicted in Table 2. Eight studies reported
the proportion of patients undergoing concomitant colorectal
resection to give a combined total of 126 of 355 patients (35%;
range: 0–50%).20–27 Liver resection was performed in all 10 studies
in a total of 443 of 453 patients (98%; range: 91–100%).18–27 Con-
comitant ablation of CLM was reported in all 10 studies in a total
of 73 of 435 patients (17%; range: 0–67%). Concomitant portal
vein ligation or PVE was reported in all 10 studies in a total of 87
of 435 patients (20%; range: 0–73%). Postoperative morbidity and
mortality were reported in all studies and affected a total of 73 of
425 patients (17%; range: 0–26%) and two of 435 patients (0.5%),
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respectively. One patient died of liver insufficiency and one died of
pulmonary embolus.
The surgical characteristics and perioperative outcomes of the
second stage of TSH are depicted in Table 3. Interval PVE was
reported in all 10 studies in a total of 262 of 430 patients (61%;
range: 0–100%). In total, 349 of the initial 459 patients (76%)
underwent portal vein ligation or embolization. Interval chemo-
therapy was reported in all 10 studies in a total of 154 of 412
patients (37%; range: 13–100%). A total of 107 patients did not
progress to the second stage of TSH. The main reasons for the
non-completion of the second stage of TSH were interval disease
progression (94 of 107 patients, 88%), followed by inadequate
FLR volume (four of 107 patients, 4%), portal vein injury or
thrombosis (four of 107 patients, 4%) and death after the first
stage of TSH (two of 107 patients, 2%). Of the initial 459 patients,
352 (77%) ultimately underwent the second stage of TSH. Liver
resection was performed in 346 of 352 patients (98%), 290 (84%)
of whom underwent major liver resections. Seven studies reported
R0 resection rates; R0 margins were achieved in a total of 158 of
210 patients (75%; range: 52–100%). Concomitant ablation of
CLM was reported in nine studies in a total of 39 of 314 patients
(12%; range: 0–59%). Postoperative morbidity and mortality were
reported in all 10 studies and affected a total of 146 of 365 patients
(40%; range: 20–56%) and 11 of 347 patients (3%), respectively.
All 11 postoperative deaths were secondary to liver insufficiency.
Thus, TSH was completed in 346 patients. Survival outcomes
after completion of TSH are depicted in Table 4. Eight studies
reported median follow-up time, giving a median value of 27
months (range: 12–50 months). Survival outcomes were reported
in all 10 studies. Median DFS was reported in four studies (141 of
346 patients), which gave values of 8 months, 9 months, 12
months and 18 months, respectively. Three-year DFS was reported
in seven studies (272 of 346 patients) to give a median value of
20% (range: 6–27%), whereas 5-year DFS was reported in three
studies (122 of 346 patients) at values of 13%, 14% and 20%,
respectively. Median OS in patients who did not complete both
stages of TSH was reported in eight studies (106 of 113 patients)
to give a median value of 16 months (range: 10–29 months).
Median OS in patients in whom both stages of TSH were com-
pleted was reported in eight studies (277 of 346 patients) to give a
median value of 37 months (range: 24–44 months). Three-year
OS post-TSH was reported in all 10 studies to give a median value
of 59% (range: 28–84%), whereas 5-year OS post-TSH was
reported in five studies (194 of 346 patients) to give a median
value of 42% (range: 32–64%).
Discussion
This systematic review demonstrates that TSH in selected patients
with initially unresectable CLM is associated with low periopera-
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226 records after duplicates removed
226 records screened
188 records excluded
Duplicate (n = 77)
Non-human study (n = 10)
Review article (n = 27)
Case report (n = 8)
Conference abstract (n = 25)
Not relevant (n = 41)
33 full-text articles excluded
(n = 33)
Review article (n = 10)
Overlapping series (n = 7)
Series of < 10 patients (n = 3)
No survival data (n = 12)
No liver resection in first
stage (n = 1)
43 full-text articles assessed
for eligibility
10 studies included in quantitative
synthesis (meta-analysis)
10 studies included in
qualitative synthesis
5 additional records identified
through other sources
Figure 1 Flow diagram indicating the strategy used to select studies for inclusion in this review
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Table 1 Criteria used to define patients as initially unresectable
Study Year of
publication
Country Setting Study period Criteria for initial
unresectability of CLM
Criteria for selection for TSH
Turrini et al.25 2012 France Retrospective 2000–2010 Specific criteria
Inability to resect all CLM with
tumour-free margins saving
25–30% of remnant liver
volume
Not stated
Tsim et al.26 2011 UK Prospective 2003–2006 Not stated Bilobar CLM in which the left
hemiliver can be cleared of
metastases during stage 1
resection and in which 25% of
functional liver volume can be
preserved after right PVE and right/
extended right hepatectomy
Narita et al.27 2011 France Retrospective 1996–2009 Non-specific criteria
Multiple and bilobar CLM in
which it is impossible to
remove all CLM with safe
margins during a single
hepatectomy procedure
Multiple and bilobar CLM in which: (i)
clearance of the left hemiliver is
feasible during stage 1; (ii) the left
hepatic vein and pedicle are not
invaded, and (iii) FLR volume
before PVE is < 30–40% of total
functional liver volume
Muratore et al.24 2011 Italy Prospective 1997–2009 Non-specific criteria
Bilobar CLM in which a radical
resection by single
hepatectomy is not possible
Not stated
Brouquet et al.23 2011 USA Retrospective 2002–2010 Not stated Chemotherapy-responsive bilobar
CLM in which limited resection can
clear the less affected side of the
liver before the patient undergoes a
planned extended contralateral
liver resection
Surgeon must be able to resect all
CLM while preserving a sufficient
FLR (20% of total liver volume) and
adequate vascular inflow and
outflow
Bowers et al.22 2011 UK Retrospective 2004–2010 Specific criteria
Not possible to resect all disease
while retaining an FLR volume
 0.5% of body weight with
preserved vascular inflow and
outflow and biliary drainage
Not stated
Tsai et al.21 2010 USA and
Portugal
Retrospective 1994–2008 Specific criteria
Not possible to resect all CLM
while: (i) sparing two adjacent
liver segments; (ii) preserving
vascular inflow and outflow,
and (iii) maintaining adequate
remnant liver volume
Not stated
Wicherts et al.20 2008 France Prospective 1992–2007 Specific criteria
Inability to resect all CLM with
tumour-free margins and save
25–30% of liver volume
Non-specific criteria indicating that
complete removal of CLM is
possible in two sequential
resections
Pamecha et al.19 2008 UK Prospective 1999–2005 Specific criteria
Bilobar CLM in which it is
impossible to remove all CLM
while leaving remnant liver of
30%
Non-specific criteria indicating that
resection of CLM with clear
margins can be achieved leaving
sufficient FLR volume
Tanaka et al.18 2007 Japan Retrospective 1992–2004 Specific criteria with Yamanaka
prediction scorea
Specific criteria with Yamanaka
prediction score of > 60
aYamanaka prediction score = - 84.6 + 0.933A + 1.11B + 0.999C, where A = resection fraction (%) calculated from computed tomography volumetry;
B = indocyanine green retention rate at 15 minutes, and C = the age of the patient.
CLM, colorectal liver metastasis; PVE, portal vein embolization; FLR, future liver remnant; TSH, two-stage hepatectomy.
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tive morbidity and mortality and acceptable survival outcomes.
Median OS was 36 months. These outcomes are comparable with
those of liver resection in patients with resectable CLM.4–11 These
survival outcomes are encouraging when compared with the poor
survival outcomes of systematic chemotherapy alone in patients
with unresectable CLM.35 This study focused on the TSH
approach, in which liver resections are performed in each of two
separate stages of a planned procedure and which differs from
two-step liver surgery in which ablation but no resection of CLM
is performed in the first stage of the procedure.32–34 In addition,
this study differs from a previous review36 in its addition of three
more recent studies and exclusion of three studies that included
overlapping data,28–30 one study that did not report survival data31
and one study that reported two-step liver surgery.33
Although the value of liver resection in CLM has never been
demonstrated in a prospective RCT, numerous surgical series have
demonstrated the possibility of longterm survival. Additionally,
no treatment other than liver resection has shown a survival
plateau. Recently, a number of case series describing 10-year
actual survival rates after liver resection of CLM have been
published.37–39 These results support liver resection as standard
practice as well as the only curative treatment for CLM. However,
Table 2 Surgical characteristics and perioperative outcomes of the first stage of two-stage hepatectomy
Study Patients,
n
Extrahepatic
disease
Preoperative
chemotherapy,
%
Response
ratea, %
Synchronous
colorectal
resection, %
Liver
resection,
%
Ablation,
%
Operative
portal vein
ligation/
embolization, %
Postoperative
morbidity,
%
Postoperative
mortality,
%
Turrini et al.25 48 No 100 NR 37 87 67 0 10 0
Tsim et al.26 38 No 97 NR 0 100 0 0 11 0
Narita et al.27 80 Yes 84 100 40 99 31 4 14 0
Muratore et al.24 47 Yes 79 92 50 100 0 23 19 0
Brouquet et al.23 65 No 100 100 29 100 3 0 25 0
Bowers et al.22 39b Yes 74 NR 31 100 8 0 23 0
Tsai et al.21 45 Yes 71 NR 50 91 29 73 26 4c
Wicherts et al.20 59 Yes 97 100 20 100 5 56 20 0
Pamecha et al.19 14 No 100 79 NR 100 0 0 0 0
Tanaka et al.18 24 No 64 NR NR 100 0 71 13 0
Total 459 88 97 35 98 17 20 17
Range 64–100 79–100 0–50 87–100 0–67 4–71 0–26
aIncludes partial or stable radiological response to chemotherapy.
bSeries included patients with liver metastases from colorectal cancer (n = 33), neuroendocrine tumours (n = 3), gastrointestinal stromal tumour (n = 1),
ocular melanoma (n = 1) and salivary gland carcinoma (n = 1).
cTwo postoperative deaths: one from liver insufficiency and one from pulmonary embolus.
NR, not reported.
Table 3 Surgical characteristics and perioperative outcomes of the second stage of two-stage hepatectomy
Study Interval
portal vein
embolization,
%
Interval
chemotherapy,
%
Patients,
n
Proportion
of patients
selected for
stage 2, %
Liver
resection,
%
Major
liver
resection,
%
R0
resection
rate, %
Ablation,
%
Postoperative
morbidity,
%
Postoperative
mortality,
%
Turrini et al.25 100 29 34 71 100 91 100 59 20 6
Tsim et al.26 95 13 33 87 100 85 58 NR 33 0
Narita et al.27 92 31 61 76 100 95 NR 8 54 0
Muratore et al.24 57 53 36 77 100 94 86 0 44 0
Brouquet et al.23 70 19 47 72 100 85 64 0 49 6
Bowers et al.22 72 15 32 82 84 59 52 7 56 4
Tsai et al.21 4 62 35 78 97 80 NR 20 26 6
Wicherts et al.20 20 78 41 69 100 76 NR 12 59 7
Pamecha et al.19 14 100 11 79 100 73 100 0 27 0
Tanaka et al.18 0 0 22 92 100 67 87 0 23 0
Total 61 37 352 77 98 84 75 12 40 3
Range 0–100 0–100 69–92 84–100 59–95 52–100 0–59 20–59 0–7
NR, not reported.
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only 10% of patients were candidates for liver resection when
traditional criteria for the resectability of CLM were applied
(namely, up to three unilobar metastases that are resectable with a
generous margin of healthy liver tissue40). Over the past decade,
considerable effort has been focused on the development of inno-
vative approaches to improve resectability of CLM.41 These
include downstaging chemotherapy followed by rescue liver resec-
tion, preoperative PVE followed by liver resection, the use of abla-
tive therapy and TSH.14,42–44
The studies included in this systematic review are not uniform
in their definitions of the technical unresectability of CLM. There
is a significant lack of agreement among liver surgeons on what
constitutes resectability and the appropriate use of adjuvant
modalities in the treatment of CLM.45 Similarly, up to a third of
patients initially labelled as unresectable are reclassified as resect-
able following review by a multidisciplinary oncology team.46 This
lack of agreement even among experts significantly limits the
critical evaluation of outcomes of TSH in patients with initially
unresectable CLM. Standardization of technical resectability cri-
teria will clearly facilitate a better understanding of the roles of
preoperative and interval chemotherapy, as well as that of PVE, in
patients with initially unresectable CLM. In 2006, a consensus
group proposed that there should be a paradigm shift in the
definition of resectability and that the consideration of resectabil-
ity should focus on what will remain after resection rather than on
what is to be removed. Three specific criteria for resectability of
CLM were proposed: (i) the preservation of two contiguous liver
segments; (ii) the preservation of adequate vascular inflow and
outflow and biliary drainage, and (iii) the preservation of an
adequate FLR (> 20% in a healthy liver).47 The widespread
adoption of uniform definitions will clearly facilitate the interpre-
tation of future results.
Another limitation to the interpretation of the data included in
this systematic review concerns the lack of uniform criteria for
patient selection for TSH. All of the studies included were
reported from high-volume hepatobiliary cancer surgery centres
and thus an aggressive surgical approach could reasonably be
assumed. Parameters based on the sizes, numbers and locations of
CLM lesions were not used as contraindications for TSH. Three of
the studies included suggested that TSH should be considered in
patients with unresectable bilobar CLM in whom one affected side
of the liver can be resected during the first stage and all remaining
CLM can be resected in a planned second hepatectomy, preserving
sufficient FLR volume. Nevertheless, patients scheduled for TSH
are highly selected and represent only a small proportion of
patients with CLM. Two-stage hepatectomy should be considered
only if a one-stage hepatectomy cannot be performed even with
the use of preoperative PVE and ablative therapies. Adam et al.
proposed a classification of multinodular CLM depending on the
number, size and location of metastases.48 It was suggested that
TSH should be considered in selected patients with bilobar multi-
nodular CLM in whom a right hepatectomy would leave more
than three metastases or any metastasis of >3 cm in the FLR.
Modern chemotherapy regimens using the combination of
5-fluorouracil (5-FU) plus oxaliplatin and/or irinotecan have pro-
duced impressive response rates in patients with CLM. Partial
response rates of up to 50% and median survival approaching 2
years have been reported.49,50 The addition of biological agents
such as bevacizumab and cetuximab has been shown to further
improve response rate.46,51 One systematic review demonstrated
Table 4 Survival outcomes after completion of two-stage hepatectomy
Study Median
follow-up,
months
Median DFS
post-TSH,
months
3-year DFS
post-TSH, %
5-year DFS
post-TSH, %
Median OS in
non-completion
of TSH, months
Median OS
post-TSH,
months
3-year OS
post-TSH, %
5-year OS
post-TSH, %
Turrini et al.25 41 NR 24 14 19 44 59 35
Tsim et al.26 19 18a 27a NR 29 35 50a NR
Narita et al.27 30 NR 15b 8b 19 40 59 32
Muratore et al.24 24d 8 10 NR 12 38 65 NR
Brouquet et al.23 50 NR 20 20 25 NR 84 64
Bowers et al.22 12 NR NR NR 10c 24c 28c NR
Tsai et al.21 NR NR NR NR 10 36 58 NR
Wicherts et al.20 24 NR 26 13 11 39 60 42
Pamecha et al.19 43 12 NR NR NR 33 70 50
Tanaka et al.18 NR NR 6 NR NR NR 33 NR
Median 27 20 16 37 59 42
Range 12–50 6–27 10–29 24–44 28–84 32–64
aIn patients with R0 liver resection.
bIn patients who underwent preoperative chemotherapy.
cSurvival outcomes in patients with CLM only.
dMean value.
TSH, two-stage hepatectomy; CLM, colorectal liver metastases; NR, not reported; DFS, disease-free survival; OS, overall survival.
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that downstaging chemotherapy could convert almost a quarter of
patients with initially unresectable CLM into resection candi-
dates.43 Despite the increased efficacy of chemotherapy in patients
with CLM, its use is not without risk. There is concern that
chemotherapy-associated liver injury might have a negative
impact on perioperative outcomes in patients undergoing resec-
tion of CLM. Liver steatosis and steatohepatitis have been shown
to be associated with 5-FU and irinotecan exposure, respectively,
whereas sinusoidal liver injury is a potential consequence of oxali-
platin treatment.52 Previous studies have shown increased periop-
erative mortality in patients with chemotherapy-associated
steatohepatitis. Increased perioperative bleeding has been associ-
ated with chemotherapy-associated sinusoidal liver injury.53
Vauthey et al. therefore advocated a ‘20/30/40’ rule to ensure the
safety of liver resection: an FLR representing a minimum of 20%
of liver volume is required in normal liver; an FLR representing
30% of liver volume is required in chemotherapy-damaged liver,
and an FLR representing 40% of liver volume is required in cir-
rhotic liver.54 In this analysis, preoperative chemotherapy was used
in 88% of patients selected for TSH. This high rate of chemo-
therapy administered before resection is probably related to the
extent and perceived unresectability of CLM in these patients. The
rationale for preoperative chemotherapy includes an opportunity
to demonstrate chemotherapy-specific efficacy as well as a lower
rate of positive margins.55 The objective response to preoperative
chemotherapy has also been shown to be a strong predictor of
survival after resection of CLM.56,57 One study included in this
systematic review reported response to preoperative chemo-
therapy on imaging as part of its patient selection criteria for
TSH.23 In the present analysis, the dropout rate after the first stage
of TSH was 24%, mainly as a result of disease progression. Previ-
ous experimental studies have shown that both liver resection and
PVE stimulated increased expression of growth factors and thus
residual tumour growth.58,59 Interval chemotherapy has thus been
proposed as a strategy to halt tumour progression between the
first and second stages of TSH.24 In the studies analysed in this
review, interval chemotherapy was used in 37% of cases. One
study examined the impact of interval chemotherapy according to
the rate of disease progression and dropout between the first and
second stages of TSH.24 However, the use of interval chemo-
therapy with 5-FU plus oxaliplatin or irinotecan did not signifi-
cantly affect rates of disease progression and dropout.
Both postoperative morbidity (40% versus 17%) and mortality
(3% versus 0.5%) were higher in the second than the first stage of
TSH. All of the 11 postoperative fatalities that occurred after the
second stage of TSH were related to liver insufficiency. These
deaths occurred despite the high rate of PVE used (76% of the
initial 459 patients selected for TSH). Previous reports have dem-
onstrated that the uniform delivery of PVE before major liver
resection does not influence postoperative morbidity or mortal-
ity.60 Portal vein embolization is therefore indicated only in
patients in whom liver resection is technically feasible but would
leave an insufficient FLR volume.
In this study, a pooled analysis in which the data from obser-
vational studies were combined as if they were derived from a
single sample was conducted. The application of any formal meta-
analytic methods, particularly simple pooling, to observational
studies has been considered controversial.61 Although combining
data by meta-analytic methods is preferable, it was not feasible in
this study.62 It should be acknowledged that the studies in this
review each included a small number of resectable patients and
that considerable heterogeneity was evident across designs. Nev-
ertheless, the pooling of data provides an indication of real-world
outcomes, but the subsequent results should be interpreted with
caution.
In conclusion, this systematic review demonstrates that TSH is
associated with acceptable perioperative and survival outcomes in
patients with initially unresectable CLM. These results are com-
parable with those in patients with initially resectable disease.
Further prospective controlled studies are required to better
define criteria for the selection of patients for TSH and the exact
roles of preoperative and interval chemotherapy and PVE.
Conflicts of interest
None declared.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics,
2002. CA Cancer J Clin 55:74–108.
2. Steele GJ, Ravikumar TS. (1989) Resection of hepatic metastases from
colorectal metastases: biologic perspectives. Ann Surg 210:127–138.
3. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibar-
tolomeo M et al. (2009) Safety and efficacy of first-line bevacizumab with
FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal
cancer: the BEAT study. Ann Oncol 20:1842–1847.
4. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al.
(2004) Recurrence and outcomes following hepatic resection, radiofre-
quency ablation, and combined resection/ablation for colorectal liver
metastases. Ann Surg 239:818–825; discussion 825–827.
5. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R,
Schulick RD et al. (2002) Trends in longterm survival following liver resec-
tion for hepatic colorectal metastases. Ann Surg 235:759–766.
6. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg
SM. (2004) Five-year survival after resection of hepatic metastases from
colorectal cancer in patients screened by positron emission tomography
with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438–447; dis-
cussion 447–450.
7. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. (1999) Clinical
score for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg
230:309–318; discussion 318–321.
8. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T
et al. (2000) Extension of the frontiers of surgical indications in the treat-
ment of liver metastases from colorectal cancer: longterm results. Ann
Surg 231:487–499.
9. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier
P et al. (1996) Surgical resection of colorectal carcinoma metastases to
HPB 489
HPB 2013, 15, 483–491 © 2012 International Hepato-Pancreato-Biliary Association
the liver. A prognostic scoring system to improve case selection, based
on 1568 patients. Association Française de Chirurgie. Cancer 77:1254–
1262.
10. Rees M, Tekkis PP, Welsh FKS, O'Rourke T, John TG. (2008)
Evaluation of longterm survival after hepatic resection for metastatic
colorectal cancer: a multifactorial model of 929 patients. Ann Surg
247:125–135.
11. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. (1995) Resection of
colorectal liver metastases. World J Surg 19:59–71.
12. Adson MA. (1987) Resection of liver metastases – when is it worthwhile?
World J Surg 11:511–520.
13. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D et al.
(1996) Resection of non-resectable liver metastases from colorectal
cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522.
14. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. (2000) Two-stage
hepatectomy: a planned strategy to treat irresectable liver tumours. Ann
Surg 232:777–785.
15. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The
Newcastle–Ottawa Scale (NOS) for assessing the quality of non-
randomized studies in meta-analyses. Third Symposium on Systematic
Reviews: Beyond the Basics. Oxford, 3–5 July 2000.
16. National Health and Medical Research Council. (1999) A Guide to the
Development, Implementation and Evaluation of Clinical Practice Guide-
lines. Canberra, ACT: AusInfo.
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP
et al. (2009) The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care interventions: expla-
nation and elaboration. J Clin Epidemiol 62:1–34.
18. Tanaka K, Shimada H, Matsuo K, Ueda M, Endo I, Togo S.
(2007) Remnant liver regeneration after two-stage hepatectomy for
multiple bilobar colorectal metastases. Eur J Surg Oncol 33:329–
335.
19. Pamecha V, Nedjat-Shokouhi B, Gurusamy K, Glantzounis GK, Sharma
D, Davidson BR. (2008) Prospective evaluation of two-stage hepatec-
tomy combined with selective portal vein embolization and systemic
chemotherapy for patients with unresectable bilobar colorectal liver
metastases. Dig Surg 25:387–393.
20. Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan L-A et al.
(2008) Longterm results of two-stage hepatectomy for irresectable color-
ectal cancer liver metastases. Ann Surg 248:994–1005.
21. Tsai S, Marques HP, De Jong MC, Mira P, Ribeiro V, Choti MA et al.
(2010) Two-stage strategy for patients with extensive bilateral colorectal
liver metastases. HPB 12:262–269.
22. Bowers KA, O'Reilly D, Bond-Smith GE, Hutchins RR. (2011) Feasibility
study of two-stage hepatectomy for bilobar liver metastases. Am J Surg
203:691–697.
23. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C et al.
(2011) High survival rate after two-stage resection of advanced colorectal
liver metastases: response-based selection and complete resection
define outcome. J Clin Oncol 29:1083–1090.
24. Muratore A, Zimmitti G, Ribero D, Mellano A, Viganò L, Capussotti L.
(2011) Chemotherapy between the first and second stages of a two-
stage hepatectomy for colorectal liver metastases: should we routinely
recommend it? Ann Surg Oncol 19:1310–1315.
25. Turrini O, Ewald J, Viret F, Sarran A, Goncalves A, Delpero JR. (2012)
Two-stage hepatectomy: who will not jump over the second hurdle? Eur
J Surg Oncol 38:266–273.
26. Tsim N, Healey AJ, Frampton AE, Habib NA, Bansi DS, Wasan H et al.
(2011) Two-stage resection for bilobar colorectal liver metastases: R0
resection is the key. Ann Surg Oncol 18:1939–1946.
27. Narita M, Oussoultzoglou E, Jaeck D, Fuchschuber P, Rosso E, Pessaux
P et al. (2011) Two-stage hepatectomy for multiple bilobar colorectal liver
metastases. Br J Surg 98:1463–1475.
28. Karoui M, Viganò L, Goyer P, Ferrero A, Luciani A, Aglietta M et al. (2010)
Combined first-stage hepatectomy and colorectal resection in a two-
stage hepatectomy strategy for bilobar synchronous liver metastases. Br
J Surg 97:1354–1362.
29. Tanaka K, Kumamoto T, Nojiri K, Takeda K, Ichikawa Y, Endo I. (2012)
Timing of two-stage liver resection during chemotherapy for otherwise
unresectable colorectal metastases. World J Surg 36:1832–1841.
30. Togo S, Nagano Y, Masui H, Tanaka K, Miura Y, Morioka D et al. (2005)
Two-stage hepatectomy for multiple bilobular liver metastases from
colorectal cancer. Hepatogastroenterology 52:913–919.
31. Homayounfar K, Liersch T, Schuetze G, Niessner M, Goralczyk A, Meller
J et al. (2008) Two-stage hepatectomy (R0) with portal vein ligation –
towards curing patients with extended bilobular colorectal liver metas-
tases. Int J Colorectal Dis 24:409–418.
32. Lygidakis NJ, Bhagat AD, Vrachnos P, Grigorakos L. (2007) Challenges in
everyday surgical practice: synchronous bilobar hepatic colorectal
metastases – newer multimodality approach. Hepatogastroenterology
54:1020–1024.
33. Lygidakis NJ, Singh G, Bardaxoglou E, Dedemadi G, Sgourakis G,
Nestoridis J et al. (2004) Two-stage liver surgery for advanced liver
metastasis synchronous with colorectal tumour. Hepatogastroenterology
51:413–418.
34. Lygidakis NJ, Vlachos L, Raptis S, Rassidakis G, Balaskas C, Sgourakis
G et al. (1999) New frontiers in liver surgery. Two-stage liver surgery for
the management of advanced metastatic liver disease. Hepatogastroen-
terology 46:2216–2228.
35. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al.
(2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal
cancer. Irinotecan Study Group. N Engl J Med 343:905–914.
36. Chua TC, Liauw W, Chu F, Morris DL. (2012) Summary outcomes of
two-stage resection for advanced colorectal liver metastases. J Surg
Oncol (In Press).
37. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M
et al. (2007) Actual 10-year survival after resection of colorectal liver
metastases defines cure. J Clin Oncol 25:4575–4580.
38. Viganò L, Ferrero A, Lo Tesoriere R, Capussotti L. (2008) Liver surgery for
colorectal metastases: results after 10 years of follow-up. Longterm
survivors, late recurrences, and prognostic role of morbidity. Ann Surg
Oncol 15:2458–2464.
39. Pulitanò C, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW,
Ferla G et al. (2010) What defines ‘cure’ after liver resection for
colorectal metastases? Results after 10 years of follow-up. HPB 12:244–
249.
40. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF et al.
(2008) Urgent need for a new staging system in advanced colorectal
cancer. J Clin Oncol 26:4828–4833.
41. Khatri VP, Petrelli NJ, Belghiti J. (2005) Extending the frontiers of surgical
therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol
23:8490–8499.
42. Elias D, Baton O, Sideris L, Boige V, Malka D, Liberale G et al.
(2005) Hepatectomy plus intraoperative radiofrequency ablation and
490 HPB
HPB 2013, 15, 483–491 © 2012 International Hepato-Pancreato-Biliary Association
chemotherapy to treat technically unresectable multiple colorectal liver
metastases. J Surg Oncol 90:36–42.
43. Lam VWT, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HCC
et al. (2012) A systematic review of clinical response and survival out-
comes of downsizing systemic chemotherapy and rescue liver surgery in
patients with initially unresectable colorectal liver metastases. Ann Surg
Oncol 19:1292–1301.
44. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A et al. (2000)
Resection of non-resectable liver metastases from colorectal cancer after
percutaneous portal vein embolization. Ann Surg 231:480–486.
45. MohammadWM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa
FK. (2012) Evaluating agreement regarding the resectability of colorectal
liver metastases: a national case-based survey of hepatic surgeons. HPB
14:291–297.
46. Folprecht G, Gruenberger T, Bechstein WO, Raab R, Lordick F, Hartmann
JT et al. (2010) Tumour response and secondary resectability of colorec-
tal liver metastases following neoadjuvant chemotherapy with cetuximan:
the CELIM randomized phase 2 trial. Lancet Oncol 11:38–47.
47. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA.
(2006) Selection of patients for resection of hepatic colorectal metas-
tases: expert consensus statement. Ann Surg Oncol 13:1261–1268.
48. Adam R, Miller R, Pitombo M, Wicherts DA, de Haas RJ, Bitsakou G et al.
(2007) Two-stage hepatectomy approach for initially unresectable color-
ectal hepatic metastases. Surg Oncol Clin N Am 16:525–536.
49. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al.
(2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line
treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947.
50. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al.
(2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in
advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol
22:229–237.
51. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S et al.
(2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil,
and folinate) as first-line treatment for metastatic colorectal cancer: a
phase 2 trial. Lancet Oncol 11:845–852.
52. Khan AZ, Morris-Stiff G, Makuuchi M. (2009) Patterns of chemotherapy-
induced hepatic injury and their implications for patients undergoing liver
resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg
16:137–144.
53. Morris-Stiff G, Tan Y-M, Vauthey JN. (2008) Hepatic complications fol-
lowing preoperative chemotherapy with oxaliplatin or irinotecan for
hepatic colorectal metastases. Eur J Surg Oncol 34:609–614.
54. Vauthey JN, Abbott DE. (2012) Commentary on ‘Feasibility study of
two-stage hepatectomy for bilobar liver metastases’. Am J Surg
203:698–699.
55. Benoist S, Nordlinger B. (2009) The role of preoperative chemotherapy in
patients with resectable colorectal liver metastases. Ann Surg Oncol
16:2385–2390.
56. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B et al. (2004)
Tumour progression while on chemotherapy: a contraindication to liver
resection for multiple colorectal metastases? Ann Surg 240:1052–1061;
discussion 1061–1064.
57. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ et al.
(2008) Pathologic response to preoperative chemotherapy: a new
outcome endpoint after resection of hepatic colorectal metastases. J Clin
Oncol 26:5344–5351.
58. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD.
(2010) Tumour growth following portal branch ligation in an experimental
model of liver metastases. Br J Surg 97:917–926.
59. Meredith K, Haemmerich D, Qi C, Mahvi D. (2007) Hepatic resection but
not radiofrequency ablation results in tumour growth and increased
growth factor expression. Ann Surg 245:771–776.
60. Farges O, Belghiti J, Kianmanesh R, Regimbeau J-M, Santoro R, Vilgrain
V et al. (2003) Portal vein embolization before right hepatectomy: pro-
spective clinical trial. Ann Surg 237:208–217.
61. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich
C. (1999) Traditional reviews, meta-analyses and pooled analyses in
epidemiology. Int J Epidemiol 28:1–9.
62. Bravata DM, Olkin I. (2001) Simple pooling versus combining in meta-
analysis. Eval Health Prof 24:218–230.
HPB 491
HPB 2013, 15, 483–491 © 2012 International Hepato-Pancreato-Biliary Association
